Dr. Stanley’s lab has identified many of the genes and syndromes associated with congenital hyperinsulinism including ABCC8, GCK, GLUD1, and Turner and Beckwith syndromes. Working with clinical and rodent model studies, his lab team has identified distinctive phenotypes of these disorders, including diazoxide unresponsiveness, leucine sensitivity, and protein sensitivity. Dr. Stanley continues to seek new diagnostic and treatment paradigms for infants with acquired and genetic disorders of hyperinsulinism.
The founder and director of CHOP's Center for Fetal Diagnosis and Treatment, Dr. Adzick is an innovator in the field of fetal medicine, pursuing groundbreaking prenatal treatment for debilitating birth defects. He led the NIH-funded "Management of Myelomeningocele Study" (MOMS) at CHOP, a breakthrough research program that showed fetal surgery for spina bifida results in significantly improved outcomes.
As a pediatric endocrinologist and director of the Congenital Hyperinsulinism Center at Children's Hospital of Philadelphia (CHOP), Diva De León-Crutchlow, MD, specializes in the diagnosis and management of hyperinsulinism (HI) and other hypoglycemia disorders.